This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hofland, K. F. Articles by Jensen, P. B. Search for Related Content PubMed PubMed Citation Articles by Hofland, K. F. Articles by Jensen, P. B.

Combining Etoposide and Dexrazoxane Synergizes with Radiotherapy and Improves Survival in Mice with Central Nervous System Tumors

Authors' Affiliations: ¹ Laboratory of Experimental Medical Oncology, The Finsen Center; ² Department of Pathology, The Laboratory Center, The National University Hospital; ³ Institute of Molecular Pathology, University of Copenhagen; and ⁴ TopoTarget A/S, Copenhagen, Denmark

Requests for reprints: Kenneth Francis Hofland, TopoTarget A/S, Fruebjergvej 3, Copenhagen DK-2100, Denmark. Phone: 45-3-917-8389; Fax: 45-3-917-9492; E-mail: kfh{at}topotarget.com.

Purpose: The treatment of patients with brain metastases is presently ineffective, but cerebral chemoradiotherapy using radiosensitizing agents seems promising. Etoposide targets topoisomerase II, resulting in lethal DNA breaks; such lesions may increase the effect of irradiation, which also depends on DNA damage. Coadministration of the topoisomerase II catalytic inhibitor dexrazoxane in mice allows for more than 3-fold higher dosing of etoposide. We hypothesized that dexrazoxane combined with escalated etoposide doses might improve the efficacy of cerebral radiotherapy.

Experimental Design: Mice with cerebrally inoculated Ehrlich ascites tumor (EHR2) cells were treated with combinations of etoposide + dexrazoxane + cerebral radiotherapy. Similar chemotherapy and radiation combinations were investigated by clonogenic assays using EHR2 cells, and by DNA double-strand break assay through quantification of phosphorylated histone H2AX (H2AX).

Results: Escalated etoposide dosing (90 mg/kg) combined with dexrazoxane (125 mg/kg) and cerebral radiotherapy (10 Gy x 1) increased the median survival by 60% (P = 0.001) without increased toxicity, suggesting that escalated etoposide levels may indeed represent a new strategy for improving radiotherapy. Interestingly, 125 mg/kg dexrazoxane combined with normal etoposide doses (34 mg/kg) also increased survival from radiotherapy, but only by 27% (P = 0.002). This indicates a direct dexrazoxane modulation of the combined effects of etoposide and radiation in brain tumors. Further, in vitro, concurrent dexrazoxane, etoposide, and irradiation significantly increased DNA double-strand breaks.

Conclusion: Combining etoposide (high or normal doses) and dexrazoxane synergizes with cerebral radiotherapy and significantly improves survival in mice with central nervous system tumors. This regimen may thus improve radiation therapy of central nervous system tumors.

This article has been cited by other articles:

				M. Grauslund, A. V. Thougaard, A. Fuchtbauer, K. F. Hofland, P. H. Hjorth, P. B. Jensen, M. Sehested, E.-M. Fuchtbauer, and L. H. Jensen A Mouse Model for Studying the Interaction of Bisdioxopiperazines with Topoisomerase II{alpha} in Vivo Mol. Pharmacol., October 1, 2007; 72(4): 1003 - 1014. [Abstract] [Full Text] [PDF]

				L. H. Jensen, H. Liang, R. Shoemaker, M. Grauslund, M. Sehested, and B. B. Hasinoff A Three-Dimensional Quantitative Structure-Activity Relationship Study of the Inhibition of the ATPase Activity and the Strand Passing Catalytic Activity of Topoisomerase II{alpha} by Substituted Purine Analogs Mol. Pharmacol., November 1, 2006; 70(5): 1503 - 1513. [Abstract] [Full Text] [PDF]